Biotech Values

[NP1986]

Afatinib had disappointing results in one of its phase III studies (although I don't recall any results presented for a confirmed T790M subgroup - I believe results based on the EGFR mutation analysis are still pending), but I'm not aware of any other failures in T790M patients - at least for agents that have shown preclinical activity against this target.

Nonetheless, if it turns out that drugs like afatinib and PF-804 lack efficacy in the T790M patients, then it won't bode well for '113.